Cancer – STRIvE-02: A Phase 1 Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Condition or Therapy:
What is the goal of this study?
STRIvE-02 is a phase 1 clinical trial. Phase 1 trials focus on finding out how much of a therapy to give, how to give it, how often to give it and when side effects occur. Through the STRIvE-02 studies, researchers are working to answer these questions:
- Is T-cell therapy safe to give to children and young adults with relapsed or refractory solid tumors?
- What is the best dose of CAR T cells for children and young adults with solid tumors?
- Does T-cell therapy work against solid tumors?
Who can join the study?
This STRIvE-02 study is for children and young adults who:
- Have relapsed or refractory solid tumors that express the protein B7H3
- Are ages 0 to 26 years old
Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.
What will happen if my child takes part in this study?
In this trial, the patient’s own T cells are reprogrammed to recognize and target the protein B7H3, which is expressed by many childhood solid tumors, including rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, Wilms tumor, neuroblastoma and others.
You can read about the STRIvE-02 study protocol on clinicaltrials.gov.